NRG Oncology Network Group Operations Center

NRG 肿瘤网络集团运营中心

• 批准号: 10731902
• 负责人: Quynh-Thu Xuan Le
• 金额: $ 109.42万
• 依托单位: NRG ONCOLOGY FOUNDATION, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10731902
• 关键词: Adult; African ancestry; Area; Awareness; Brain Neoplasms; Breast; Cancer Patient; Cancer Therapy Evaluation Program; Clinical Research; Clinical Trials; Collaborations; Development; Disease; Enrollment; Ensure; Gender; Goals; Gynecologic; Head and Neck Cancer; Hispanic; International; Latino; Lead; Leadership; Locally Advanced Malignant Neoplasm; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Malignant neoplasm of prostate; Malignant neoplasm of urinary bladder; Manuscripts; National Clinical Trials Network; Non-Hematologic Malignancy; Oncology; Patients; Peer Review; Positioning Attribute; Precision medicine trial; Protocols documentation; Publishing; Research; Scientific Advances and Accomplishments; Site; Translational Research; advanced disease; advanced prostate cancer; clinically relevant; cohort; design; improved; interest; malignant breast neoplasm; member; multidisciplinary; operation; participant enrollment; patient population; sarcoma; trial enrollment

NRG Overall Component Abstract NRG Oncology (NRG) has made significant progress toward its goal of improving the lives of adults with certain non-hematologic malignancies through its clinical and translational research efforts. NRG's defined patient populations of interest - those with gender-specific malignancies and/or those with localized or locally advanced disease, are unique within the NCTN, constituting a large and relatively under-investigated cohort of cancer patients. Positioned to be the lead NCTN research organization for trials enrolling several patient cohorts, NRG's portfolio focuses on patients with gynecologic cancer, primary or secondary brain tumors, head and neck cancer, or localized or locally advanced prostate cancer as well as breast cancer, lung cancer, gastrointestinal cancer, bladder cancer, or sarcoma. In these and other realms NRG, actively collaborates with other NCTN groups, diligently working to increase awareness of and participation in all NCTN trials. NRG's research accomplishments to date have been extraordinary. There have been 87 CTEP- supported NRG trials open for enrollment during this period, representing 34% of the open NCTN adult trials. For the period March 1, 2014 through August 31, 2017, NRG members entered 10,840 patients onto NRG-led trials, 3,199 patients into trials led by other NCTN network groups, and an additional 1,906 patients onto NCTN Precision Medicine Trials for a total of 15,945 entries. Of the 48,056 total NCTN treatment enrollments, NRG's contribution accounts for 33% of the total entries and represents the largest accrual of any of the five NCTN groups. Of patients enrolled onto NRG trials at U.S. sites, 12.7% were self-identified as of African descent and 8.0% as Latino or Hispanic. There have been 302 NRG peer-reviewed manuscripts published or in press and 365 published abstracts during this period, of which at least 52 contain practice-changing or practice-defining observations. To successfully fulfill its ambitious goal, NRG has seven cancer disease site committees, all with internationally recognized multi-disciplinary leadership and all with strong liaison representatives from NRG's nine scientific core committees. There are four other protocol-generating committees and five administrative committees, all designed to lead and support critical areas of the group's research. NRG is organized such that the necessary operational efficiencies and internal peer review are in order to overcome barriers to conducting a broad portfolio of scientifically important and relevant clinical trials and to ensuring appropriate enrollment to these trials.

NRG总体组件摘要 NRG肿瘤学（NRG）已取得了重大进步，以改善其生活 通过其临床和转化研究患有某些非血液学恶性肿瘤的成年人 努力。 NRG定义的感兴趣的患者群体 - 患有性别特异性恶性肿瘤的患者群体 和/或患有局部或局部疾病的患者在NCTN中是独一无二的 构成了癌症患者的大量且相对较低的癌症队列。定位为 NRG的投资组合，NRG的主要NCTN试验研究组织招募了几个患者队列 专注于妇科癌，原发性或继发性脑肿瘤，头颈患者 癌症，局部或局部晚期前列腺癌以及乳腺癌，肺癌， 胃肠癌，膀胱癌或肉瘤。在这些和其他领域，主动 与其他NCTN小组合作，努力提高对和 参加所有NCTN试验。 NRG迄今为止的研究成就非常非凡。有87个ctep- 在此期间，支持的NRG试验开放招生，占公开的34％ NCTN成人试验。在2014年3月1日至2017年8月31日的期间，NRG成员 将10,840名患者进入NRG领导的试验，3199名患者进入由其他NCTN领导的试验 网络组，另外还有1,906名患者参加NCTN精确医学试验 总共15,945个条目。 NRG的贡献中，在48,056个NCTN治疗总计中 占总条目的33％，代表五个NCTN中的任何一个中的最大应计 组。在美国现场参加NRG试验的患者中，有12.7％的人自识别。 非洲血统和8.0％的拉丁裔或西班牙裔。 已经出版了302个NRG同行评审的手稿，或者出版了365 在此期间的摘要，其中至少有52个包含练习改变或定义的练习 观察。为了成功实现其雄心勃勃的目标，NRG有七个癌症病原 委员会，所有委员会都具有国际认可的多学科领导力，并且都有强大的领导 NRG九个科学核心委员会的联络代表。还有另外四个 协议生成委员会和五个行政委员会，旨在领导和 支持该小组研究的关键领域。 NRG的组织使得必要 运营效率和内部同行评审是为了克服进行障碍 广泛的科学重要和相关临床试验的广泛组合，并确保适当 这些试验的入学人数。